Olmesartán/Hidroclorotiazida Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartán/Hidroclorotiazida Krka, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, either alone or in combination with a diuretic, in adult patients. GNH USA supplies Olmesartán/Hidroclorotiazida Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán/Hidroclorotiazida Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil and hydrochlorothiazide is used primarily for managing high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

- Hypertension: Lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure adjunct: Assists in fluid management and blood‑pressure control when combined with other heart‑failure therapies. - Diabetic nephropathy protection: Helps slow progression of kidney damage by controlling systemic pressure. - Stroke‑risk reduction: Contributes to long‑term reduction of stroke incidence in hypertensive patients. - Post‑myocardial‑infarction care: Supports blood‑pressure targets in patients recovering from heart attacks.

Olmesartan medoxil/hydrochlorothiazide is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema involving face, lips or airway - Liver enzyme elevation - Blood dyscrasias such as agranulocytosis

When prescribing Olmesartan medoxil/hydrochlorothiazide, clinicians should consider several safety aspects.

- Renal function monitoring: Assess baseline creatinine and eGFR, then periodically during therapy. - Electrolyte surveillance: Check serum potassium and sodium levels, especially after dose changes. - Pregnancy contraindication: Avoid use in pregnancy due to fetal toxicity. - Drug‑interaction awareness: Review concomitant medications that affect potassium or renal function. - Hypotension risk: Counsel patients to rise slowly from sitting or lying positions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil/hydrochlorothiazide may interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: May cause dangerous hyper‑kalemia. - ACE inhibitors or ARBs combined with NSAIDs: Increases risk of renal impairment and hyper‑kalemia. - Lithium: May increase lithium serum concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Can blunt antihypertensive effect and affect renal function. - Antidiabetic agents: May require dose adjustments due to enhanced glucose‑lowering effect. - Antimicrobials such as trimethoprim‑sulfamethoxazole: Can affect potassium balance.